Novartis AG

Novartis AG

NVS · New York Stock Exchange

Novartis AG (NVS) is a Drug manufacturers general company in the Healthcare sector, listed on New York Stock Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Novartis AG in 2026. The next earnings report is expected on October 27, 2026.

Earnings calendar

Next earnings date

27 Oct 2026

In 67 days

EPS estimate

2.21

Revenue estimate

14.6B

Past earnings

21 Jul 2026
EPS actual
2.41 (+11.0%)
estimate 2.17
Revenue actual
14.4B (+2.4%)
estimate 14.1B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
28 Apr 2026
EPS actual
1.99 (-5.1%)
estimate 2.10
Revenue actual
13.1B (-2.4%)
estimate 13.4B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
04 Feb 2026
EPS actual
2.03 (+2.4%)
estimate 1.98
Revenue actual
13.3B (-2.7%)
estimate 13.7B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Novartis beat consensus estimates in its latest earnings report, with EPS of USD 2.41 coming in 11.0% above expectations and revenue of USD 14.41 billion exceeding estimates by 2.4%. In the prior quarter both EPS and revenue were below expectations.

Dividend calendar

Next ex-dividend

—

Not scheduled

Next payment

—

Not scheduled

Dividend amount

—

Not available

Past dividends

Ex-dividend Payment Amount
11 Mar 2026 16 Mar 2026 3.08

EPS (Earnings Per Share)

Revenue

Dividend per share

Company profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sector
Healthcare
Industry
Drug manufacturers general
Country
Switzerland
Exchange
New York Stock Exchange
CEO
Vasant Narasimhan
Employees
75,883
IPO date
07 Nov 1996
ISIN
US66987V1098
Website
novartis.com

Frequently asked questions

When does Novartis AG (NVS) next report earnings?

Novartis AG (NVS) is scheduled to report earnings on October 27, 2026.

What was Novartis AG's most recent earnings date?

Novartis AG (NVS) last reported earnings on July 21, 2026.

Where is Novartis AG stock listed?

Novartis AG (NVS) is listed on New York Stock Exchange.